GLP-1 adjacencies in longevity practice — what sits inside and outside the prescription line.

GLP-1 receptor agonists are physician-prescribed pharmaceuticals; nothing about that changes. What is changing is the practitioner-side stack that surrounds them: structured body-composition tracking, lean-mass preservation protocols, micronutrient support to address well-documented deficiencies in chronic GLP-1 use, and the patient-education work that decides whether a metabolic intervention compounds or stalls. Practices building durable longevity programmes are codifying this work — visit cadence, supplementation schedule, monitoring protocol — rather than treating it as a clinic-by-clinic improvisation. The evidence base for the surrounding stack is heterogeneous; reading it carefully separates a defensible programme from one that will not survive the first regulator conversation.